Significant Accounting Policies - Additional Information (Details) - USD ($)					3 Months Ended			12 Months Ended
	Jan. 14, 2022	Oct. 12, 2021	Mar. 19, 2021	Jan. 25, 2021	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2021	Oct. 04, 2021
Schedule Of Significant Accounting Policies [Line Items]
Upfront nonrefundable payment				$ 1,000,000.0
Loan in principal amount				$ 4,000,000.0
Issuance and bore interest rate				6.00%
Reimbursement payment			$ 14,000,000.0
Collaboration agreement amount			25,000,000.0
Development payments			10,000,000.0
Deferred collaboration funding					$ 17,200,000
Deferred collaboration funding, current					17,152,362			$ 15,825,938
Cash in excess of FDIC insured limit					20,600,000			12,500,000
Cash and cash equivalents					20,800,384			12,710,762
Income tax expense (benefit)					0		$ 0
Uncertain tax positions, accruals					0		0
Accruals for interest or penalties related to income tax matters					$ 0		$ 0
ASU No. 2020-06
Schedule Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted					true
Change in accounting principle, accounting standards update, adoption date					Mar. 31, 2021
ASU No. 2021-10
Schedule Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted					true
Change in accounting principle, accounting standards update, adoption date					Dec. 31, 2021
Change in accounting principle, accounting standards update, immaterial effect					true
ASU No. 2021-04
Schedule Of Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted					true
Change in accounting principle, accounting standards update, adoption date					Mar. 31, 2022
Change in accounting principle, accounting standards update, immaterial effect					true
Accounts Payable and Accrued Expenses
Schedule Of Significant Accounting Policies [Line Items]
Preclinical or clinical study expense					$ 800,000			200,000
Event of Positive Safety
Schedule Of Significant Accounting Policies [Line Items]
Cash and cash equivalents					2,000,000.0
Maximum
Schedule Of Significant Accounting Policies [Line Items]
Cash, FDIC insured amount					250,000
Bridge Loan
Schedule Of Significant Accounting Policies [Line Items]
Cash and cash equivalents					1,500,000
Bridge Loan | Maximum
Schedule Of Significant Accounting Policies [Line Items]
Cash and cash equivalents					$ 6,500,000
Number of days required for cash balance					40 days
Bridge Loan | Minimum
Schedule Of Significant Accounting Policies [Line Items]
Cash and cash equivalents					$ 4,000,000.0
Number of days required for cash balance					20 days
Relief
Schedule Of Significant Accounting Policies [Line Items]
Non-cash reduction recognized in secured loan					$ 4,000,000.0
Collaboration Agreement | Second Development Payment
Schedule Of Significant Accounting Policies [Line Items]
Deferred collaboration funding					19,100,000
Deferred collaboration funding, current					17,200,000
Noncurrent liability					2,000,000.0
Deferred collaboration funding, cash received					35,000,000.0
Revenue recognized								$ 1,300,000
Offset to research and development expenses					9,100,000
Offset to general and administrative expenses					$ 5,600,000
Collaboration Agreement | Relief
Schedule Of Significant Accounting Policies [Line Items]
Cash payment received			10,000,000.0			$ 10,000,000.0
Reimbursement payment			14,000,000.0	$ 14,000,000.0
Repayment of outstanding balance of prior loan and interest			4,000,000.0	$ 4,000,000.0
Development and commercial launch costs			$ 20,000,000.0
Net profit split ratio based on territory			60.00%	60.00%
Percentage of royalty net sales received			15.00%	15.00%
Milestone payment to be received			$ 6,000,000.0	$ 6,000,000.0
Potential proceeds from development payments subject to new drug application									$ 10,000,000.0
Proceeds from first tranche of development payments subject to new drug application		$ 5,000,000.0
Percentage of development and commercialization services			60.00%
Percentage of payment net profit territory			60.00%
Upfront non-refundable payment received				1,000,000.0
Collaboration Agreement | Relief | Maximum
Schedule Of Significant Accounting Policies [Line Items]
Development and commercial launch costs				20,000,000.0
Development payments			$ 20,000,000.0
Collaboration Agreement | Relief | Second Development Payment
Schedule Of Significant Accounting Policies [Line Items]
Potential proceeds from development payments subject to new drug application									$ 10,000,000.0
Proceeds from first tranche of development payments subject to new drug application		5,000,000.0
Waiver and Agreement | Relief | Second Development Payment
Schedule Of Significant Accounting Policies [Line Items]
Proceeds from first tranche of development payments subject to new drug application	$ 5,000,000.0	$ 5,000,000.0
Proposed Collaboration and License Agreement
Schedule Of Significant Accounting Policies [Line Items]
Upfront non-refundable payment received			$ 1,000,000.0
Proposed Collaboration and License Agreement | Relief
Schedule Of Significant Accounting Policies [Line Items]
Upfront non-refundable payment received				$ 1,000,000.0